Literature DB >> 11404725

[Gait in patients with Parkinson's disease after surgically treated hip fracture].

B Gialanella1.   

Abstract

BACKGROUND: The aims of this study were: 1) to evaluate the degree of walking of patients with Parkinson s syndrome after hip fracture surgically treated; 2) to reexamine the evidence for internal fixation versus endoprosthesis.
METHODS: Forty-one patients with Parkinson s syndrome after hip fracture surgically treated have been studied. Twenty-four fractures (20 femoral neck, 4 subcapital) were treated by endoprosthesis, and 17 by internal fixation (pertrochanteric fractures). The average age of the patients was 76+/-7 years (7 male, 34 female); 97,5% patients could walk without any help before the fracture.
RESULTS: At the end of the rehabilitation period, 21.9% patients were unable to walk; 2.4% walked with assistance of two persons, 24.4% with assistance of one person, 19.4% with two canes, 17.1% with one cane, 14.8% without assistance and without cane. At discharge, 87.5% of patients went directly back home, while the remaining 12.5% were admitted to Geriatric hospitals. The degree of walking was higher in fractures treated by endoprosthesis (p<0.05). At the end of treatment, 62.5% fractures treated by endoprosthesis and 35.2% treated by internal fixation could walk without any help. IN
CONCLUSION: 1) Parkinson s disease influences the recovery of walking after hip fracture; 2) At the end of rehabilitation, the parkinsonian patients with hip fractures treated by endoprosthesis showed better results than those treated by internal fixation.

Entities:  

Mesh:

Year:  2001        PMID: 11404725

Source DB:  PubMed          Journal:  Minerva Med        ISSN: 0026-4806            Impact factor:   4.806


  1 in total

1.  Parkinson's disease influences the perioperative risk profile in surgery.

Authors:  Marcus C Mueller; Ulf Jüptner; Ullrich Wuellner; Stefan Wirz; Andreas Türler; Andreas Hirner; Jens Standop
Journal:  Langenbecks Arch Surg       Date:  2008-08-19       Impact factor: 3.445

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.